Lexicon Pharmaceuticals LXRX Excess tax benefits associated with employee equity plans
Excess tax benefits associated with employee equity plans at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount.
The official record: Lexicon Pharmaceuticals’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's excess tax benefits associated with employee equity plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's excess tax benefits associated with employee equity plans?
- Lexicon Pharmaceuticals (LXRX) reported excess tax benefits associated with employee equity plans of $612.25K in Q4 2025.
- How has Lexicon Pharmaceuticals's excess tax benefits associated with employee equity plans changed year-over-year?
- Lexicon Pharmaceuticals's excess tax benefits associated with employee equity plans decreased by 34.8% year-over-year, from $939.5K to $612.25K.
- What is the long-term trend for Lexicon Pharmaceuticals's excess tax benefits associated with employee equity plans?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's excess tax benefits associated with employee equity plans has grown at a 30.2% compound annual growth rate (CAGR), from $851K to $2.45M.
- What does excess tax benefits associated with employee equity plans mean?
- The monetary value of tax benefits realized from employee equity-based compensation plans that exceed the tax deduction recorded for financial reporting purposes. This reflects the tax impact of stock-based compensation volatility relative to the company's share price performance.